Chemicals & Advanced Materials Global On demand · 24-48h

Global New Chemical Entities (NCE) CDMO Market Strategic Research Report

Global New Chemical Entities (NCE) CDMO Market Strategic Res…
$3,500 USD
Market Research Reports
Strategic Research Report
Global New Chemical Entities (NCE) CDMO Market
$3.17B2025
11.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Peptide NCE, Oligonucleotide NCE, Other

By Application: Tumors, Cardiovascular Diseases, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: KATSURA CHEMICAL CO., LTD, Regis Custom API, Neuland Laboratories Ltd., Aspen API, Sai Life Sciences, Fermion, Dipharma Francis Srl (Dipharma), Cohance, Suven Pharma, Syngene, Aarti Pharmalabs Limited (APL), Cerbios-Pharma SA, PharmaBlock Sciences Nanjing Inc

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 117 pages
Market size 2025
$3.17B
Billion USD
Forecast CAGR
11.8%
2025-2032
Forecast 2032
$6.9B
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global New Chemical Entities (NCE) CDMO market size is predicted to grow from US$ 3,172 million in 2025 to US$ 6,817 million in 2032; it is expected to grow at a CAGR of 11.8% from 2026 to 2032.

New Chemical Entities (NCE) refer to new compounds that have not yet been approved for any therapeutic use during the drug development process. These compounds are usually obtained through the synthesis or discovery of new molecules and have new activities or therapeutic potential. NCE is usually the first step in drug development, and after evaluating its safety and effectiveness in clinical trials, it may be applied for marketing. CDMO (Contract Development and Manufacturing Organization) refers to a company that provides drug development and production services, usually working with pharmaceutical companies to help them develop and manufacture NCE. CDMO can provide a range of services from preliminary compound synthesis, process development, to the production of drugs for clinical trials and commercial production. In short, NCE is a newly developed drug ingredient, and CDMO is a service provider that specializes in helping pharmaceutical companies develop and produce NCE.

Global key New Chemical Entities (NCE) CDMO players cover KATSURA CHEMICAL CO., LTD, Regis Custom API, Neuland Laboratories Ltd., Aspen API, Sai Life Sciences, etc.

This report presents a comprehensive overview of the global New Chemical Entities (NCE) CDMO market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Peptide NCE
  • Oligonucleotide NCE
  • Other

Segment by Application

  • Tumors
  • Cardiovascular Diseases
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global New Chemical Entities (NCE) CDMO market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Tumors, Cardiovascular Diseases, Other evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global New Chemical Entities (NCE) CDMO Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 11.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$3.17B
2025
Forecast
$6.9B
2032
CAGR
11.8%
2025–2032
Régions
5
global
Key companies
KATSURA CHEMICAL CO., LTDRegis Custom APINeuland Laboratories Ltd.Aspen APISai Life SciencesFermionDipharma Francis Srl (Dipharma)Cohance
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Peptide NCEOligonucleotide NCEOther
By Application
TumorsCardiovascular DiseasesOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Peptide NCE
  • 3.1.3 Oligonucleotide NCE
  • 3.1.4 Other
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Tumors
  • 4.1.3 Cardiovascular Diseases
  • 4.1.4 Other
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 KATSURA CHEMICAL CO., LTD
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Regis Custom API
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Neuland Laboratories Ltd.
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Aspen API
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Sai Life Sciences
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Fermion
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Dipharma Francis Srl (Dipharma)
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Cohance
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Suven Pharma
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Syngene
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Aarti Pharmalabs Limited (APL)
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Cerbios-Pharma SA
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 PharmaBlock Sciences Nanjing Inc
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global New Chemical Entities (NCE) CDMO market size?
The global New Chemical Entities (NCE) CDMO market is estimated at US$ 3.17 billion in 2025 (base year) and is projected to reach US$ 6.82 billion by 2032.
What growth rate is expected for the New Chemical Entities (NCE) CDMO market through 2032?
The market is expected to grow at a CAGR of 11.8% from 2026 to 2032, expanding from US$ 3.17 billion in 2025 to US$ 6.82 billion in 2032, roughly 2.2 times its base-year value.
How is New Chemical Entities (NCE) CDMO defined?
New Chemical Entities (NCE) refer to new compounds that have not yet been approved for any therapeutic use during the drug development process. These compounds are usually obtained through the synthesis or discovery of new molecules and have new activities or therapeutic potential. NCE is usually the first step in drug development, and after evaluating its safety and effectiveness in clinical trials, it may be applied for marketing.
What are the main segments of the New Chemical Entities (NCE) CDMO market by type?
By type, the market is segmented into Peptide NCE, Oligonucleotide NCE and Other.
Which applications drive demand in the New Chemical Entities (NCE) CDMO market?
Key applications covered include Tumors, Cardiovascular Diseases and Other.
Who are the key players in the New Chemical Entities (NCE) CDMO market?
Key players profiled include KATSURA CHEMICAL CO., LTD, Regis Custom API, Neuland Laboratories Ltd., Aspen API, Sai Life Sciences, Fermion, Dipharma Francis Srl (Dipharma) and Cohance, among 13 companies covered in total.
Which regions and countries are covered for New Chemical Entities (NCE) CDMO?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the New Chemical Entities (NCE) CDMO market report?
The report is intended for manufacturers and solution providers, distributors and end users in Tumors, Cardiovascular Diseases and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the New Chemical Entities (NCE) CDMO market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.